Výběr jazyka

cs
  • bg

  • cs

  • da

  • de

  • el

  • en

  • es

  • et

  • fr

  • hr

  • hu

  • it

  • lt

  • lv

  • nl

  • no

  • pl

  • pt

  • ro

  • ru

  • sk

  • sl

  • sv

  • tr

  • uk

Čeština
  • Български

  • Čeština

  • Danske

  • Deutsch

  • ελληνική

  • English

  • Español

  • Eesti keel

  • Français

  • Hrvatski

  • Magyar

  • Italiano

  • Lietuvių

  • Latviešu

  • Nederlands

  • Norsk

  • Polski

  • Português

  • Română

  • Русский

  • Slovenský

  • Slovenski

  • Svenska

  • Türkçe

  • Українська

Co si myslíte o doplnění účtu?

* Za doplnění vašeho účtu neúčtujeme žádnou provizi

Johnson&Johnson

JNJ.US $ 164.66 USD

0.94 $ (0.57%)

Potenciál růstu

12.49%

Příjem z dividend

2.75%

1d
1t
1m
6m
Celou dobu

Přidat do košíku

1 lot = 1 akcie

Částka nákupu:

Makléřská provize:

Provize za převod:

Doporučení

Strong Buy

Hodnocení výkonu

DCF

175.46

ROE

0.23

ROA

0.08

P/S

5.14

P/B

6.71

Debt / Equity

0.52

O společnosti

The American holding Johnson & Johnson specializes in the manufacture of healthcare and hygiene products. It ranks first in the world's top of companies with the largest output of medical equipment. Founded in 1886 as a family business, the company was initially engaged in the manufacture of bandaging products. The shares were put up for sale in 1944, shortly after, a thriving corporation set after swallowing up its European and North American competitors. The Company aims for the transition to the environmentally-clean manufacturing. To achieve this, a number of factories have switched to solar energy. Moreover, Johnson & Johnson avoid using plastic packaging for liquid products wherever possible. The medical specialization of the holding still stands for oncology, immunology, infectious diseases, neurology, and psychiatry. Johnson & Johnson actively invests in these areas' development. The company's current capitalization hits $317 billion. The Johnson & Johnson corporation is comprised of over 250 companies; it owns rights to over 120 brands. Alex Gorski is the Company's Director General since 2012. At the beginning of the Noughties, he was working for the Company's rivals for a while, but afterward, he returned and was rather speedily promoted. The General Director's power is not absolute; in fact, the extended holding is managed by the Board of the Company. Shares of Johnson & Johnson are rated as stable, growing in value slowly but steadily though.


Přihlaste se k odběru investičních nápadů analytiků Freedom Finance

Zprávu budeme zasílat jednou týdně, a to pouze s nejaktuálnějšími a nejdůležitějšími informacemi

Gratulujeme!

Nyní budete vždy vědět, do kterých akcií je výhodnější investovat